Cargando…

Immunogenicity of biologic therapies for migraine: a review of current evidence

BACKGROUND: Monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway have been shown to be effective in migraine prevention. Eptinezumab, erenumab, fremanezumab, and galcanezumb have shown efficacy in clinical trials along with favorable safety and tolerability profi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, Joshua M., Ning, Xiaoping, Kessler, Yoel, Rasamoelisolo, Michele, Campos, Verena Ramirez, Seminerio, Michael J., Krasenbaum, Lynda J., Shen, Honglue, Stratton, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791637/ https://www.ncbi.nlm.nih.gov/pubmed/33413094 http://dx.doi.org/10.1186/s10194-020-01211-5

Ejemplares similares

Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine
por: Mackenzie, Kimberly D., et al.
Publicado: (2022)

Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: A review
por: Rhyne, Christopher, et al.
Publicado: (2023)

Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments
por: Nissan, George R., et al.
Publicado: (2022)

Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. “Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials”. Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819–828. Epublished November 2020
por: Barash, Steve, et al.
Publicado: (2021)

Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies
por: Nahas, Stephanie J., et al.
Publicado: (2021)

Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies
por: Nahas, Stephanie J., et al.
Publicado: (2022)

Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study
por: Ashina, Messoud, et al.
Publicado: (2021)

Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine
por: Fiedler‐Kelly, Jill B., et al.
Publicado: (2019)

Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
por: Diener, Hans Christoph, et al.
Publicado: (2022)

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
por: Lipton, Richard B., et al.
Publicado: (2020)

Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System
por: Silberstein, Stephen D., et al.
Publicado: (2022)

A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled Syringe
por: Cherniakov, Irina, et al.
Publicado: (2021)

Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
por: Pazdera, Ladislav, et al.
Publicado: (2021)

Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
por: McAllister, Peter, et al.
Publicado: (2021)

Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
por: McAllister, Peter, et al.
Publicado: (2022)

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine‐preventive medications in the phase 3b FOCUS study
por: Spierings, Egilius L. H., et al.
Publicado: (2021)

Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
por: Spierings, Egilius L. H., et al.
Publicado: (2021)

The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
por: Silberstein, Stephen D., et al.
Publicado: (2020)

Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study
por: MaassenVanDenBrink, Antoinette, et al.
Publicado: (2021)

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
por: Driessen, Maurice T., et al.
Publicado: (2022)

A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States
por: Krasenbaum, Lynda J., et al.
Publicado: (2022)

Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study
por: Lipton, Richard B., et al.
Publicado: (2021)

Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study
por: Goadsby, Peter J., et al.
Publicado: (2020)

Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
por: Driessen, Maurice T., et al.
Publicado: (2022)

Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid
por: Ferrari, Michel D., et al.
Publicado: (2022)

Biological substrates of migraine
por: Calabresi, Paolo
Publicado: (2015)

Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency
por: Cohen-Barak, Orit, et al.
Publicado: (2015)

Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine
por: Friedman, Deborah I., et al.
Publicado: (2020)

Current Issues in Migraine Genetics
por: Lee, Jee-Young, et al.
Publicado: (2005)

Current Perspective on Retinal Migraine
por: Chong, Yu Jeat, et al.
Publicado: (2021)

Migraine and Current Pharmacologic Management
por: Okobi, Okelue E, et al.
Publicado: (2022)

Assessment of the Pharmacokinetics, Pharmacodynamics, and Safety of Single Doses of TV‐1106, a Long‐Acting Growth Hormone, in Healthy Japanese and Caucasian Subjects
por: Cohen‐Barak, Orit, et al.
Publicado: (2016)

An update on migraine: current understanding and future directions
por: Puledda, Francesca, et al.
Publicado: (2017)

Acute Confusional Migraine: Distinct Clinical Entity or Spectrum of Migraine Biology?
por: Farooqi, Ashar M., et al.
Publicado: (2018)

Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
por: Martinez, James M, et al.
Publicado: (2020)

Tackling chronic migraine: current perspectives
por: Carod-Artal, Francisco Javier
Publicado: (2014)

Current Treatment Options in Vestibular Migraine
por: Obermann, Mark, et al.
Publicado: (2014)

Migraine therapeutics differentially modulate the CGRP pathway
por: Bhakta, Minoti, et al.
Publicado: (2021)

Immunogenicity of biologics in inflammatory bowel disease
por: Vermeire, Séverine, et al.
Publicado: (2018)

Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines
por: Coughlan, Lynda
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pv8f5bjuupoek3jfcjh9cmrbn8